Bromelain and acetylcysteine (BromAc
BromAc
Mucins
adenocarcinoma
cancer therapy
chemo-sensitisation
pseudomyxoma peritonei
Journal
American journal of cancer research
ISSN: 2156-6976
Titre abrégé: Am J Cancer Res
Pays: United States
ID NLM: 101549944
Informations de publication
Date de publication:
2023
2023
Historique:
received:
15
03
2023
accepted:
07
04
2023
medline:
12
5
2023
pubmed:
12
5
2023
entrez:
11
5
2023
Statut:
epublish
Résumé
Mucins are a significant extracellular component of neoplastic entities such as pseudomyxoma peritonei and several gastrointestinal adenocarcinomas. Mucinous tumours present a challenge for systemic treatments due to poor drug penetrance and increased resistance. Therefore, the development of an effective mucolytic therapy has significant therapeutic implications for these tumour types. BromAc
Types de publication
Journal Article
Review
Langues
eng
Pagination
1522-1532Informations de copyright
AJCR Copyright © 2023.
Déclaration de conflit d'intérêts
Sarah J Valle and David L Morris are shareholder founders of Mucpharm Pty Ltd.
Références
Drug Discov Today. 2022 Feb;27(2):436-455
pubmed: 34624510
Int J Cancer. 2014 Jan 15;134(2):478-86
pubmed: 23843173
Orphanet J Rare Dis. 2021 Feb 13;16(1):85
pubmed: 33581733
Cancer Metastasis Rev. 2020 Sep;39(3):647-659
pubmed: 32488403
Medicine (Baltimore). 2015 Apr;94(15):e658
pubmed: 25881840
Eur J Surg Oncol. 2021 Jan;47(1):115-122
pubmed: 31679953
Clin Colorectal Cancer. 2019 Mar;18(1):1-7
pubmed: 30611664
Cancers (Basel). 2022 Mar 02;14(5):
pubmed: 35267605
Transl Res. 2021 Mar;229:100-114
pubmed: 33164812
Pharmaceuticals (Basel). 2021 Oct 17;14(10):
pubmed: 34681277
Lancet Gastroenterol Hepatol. 2022 May;7(5):455-471
pubmed: 35397245
Cancer Commun (Lond). 2019 Mar 29;39(1):13
pubmed: 30922401
Ann Surg Oncol. 2022 Apr;29(4):2144-2145
pubmed: 35006507
Br J Cancer. 2009 Oct 6;101(7):1155-61
pubmed: 19738614
Metallomics. 2018 Mar 1;10(3):414-425
pubmed: 29417972
Int J Hyperthermia. 2017 Aug;33(5):511-519
pubmed: 28540829
Am J Transl Res. 2020 Nov 15;12(11):7404-7419
pubmed: 33312377
Korean J Gastroenterol. 2020 Dec 25;76(6):297-303
pubmed: 33199672
Am J Cancer Res. 2016 Jan 15;6(2):350-69
pubmed: 27186409
Discov Oncol. 2021 Aug 16;12(1):25
pubmed: 35201475
World J Gastroenterol. 2021 Oct 28;27(40):6844-6860
pubmed: 34790010
Ann Surg Oncol. 2022 Mar;29(3):2056-2068
pubmed: 34853944
Biochim Biophys Acta. 2014 Aug;1846(1):142-51
pubmed: 24785432
Indian J Surg Oncol. 2016 Jun;7(2):152-9
pubmed: 27065705
Oncotarget. 2017 Jul 11;8(28):45698-45709
pubmed: 28501848
Cancer Metastasis Rev. 2019 Jun;38(1-2):237-257
pubmed: 30680581
Trends Mol Med. 2014 Jun;20(6):332-42
pubmed: 24667139
J Exp Clin Cancer Res. 2014 Nov 12;33:92
pubmed: 25425315
Mol Biotechnol. 2013 Jun;54(2):250-6
pubmed: 23359125
Am J Transl Res. 2022 May 15;14(5):2894-2909
pubmed: 35702130
Cancers (Basel). 2021 Mar 19;13(6):
pubmed: 33808549
Am J Cancer Res. 2014 Sep 06;4(5):495-507
pubmed: 25232491
Am J Cancer Res. 2021 May 15;11(5):2252-2263
pubmed: 34094682
Oncotarget. 2015 Oct 20;6(32):33329-44
pubmed: 26436698
Invest New Drugs. 2012 Oct;30(5):2080-6
pubmed: 22359216
J Surg Oncol. 2012 Dec;106(7):911-7
pubmed: 22585683
Case Rep Oncol. 2021 Mar 31;14(1):628-633
pubmed: 33976645
Am J Transl Res. 2021 Dec 15;13(12):13524-13539
pubmed: 35035694
J Exp Clin Cancer Res. 2018 May 21;37(1):107
pubmed: 29784019